Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

Stefano Kim, Jihane Boustani, Dewi Vernerey, Véronique Vendrely, Ludovic Evesque, Eric Francois, Laurent Quero, Francois Ghiringhelli, Christelle de la Fouchardière, Laëtitia Dahan, Oliver Bouché, Benoist Chibaudel, Farid El Hajbi, Chloé Vernet, Magali Rebucci-Peixoto, Alexandra Feuersinger, Christophe Maritaz, Christophe Borg

Open source

DOI: 10.3389/fonc.2022.918499
Published: 2022-08-24
Container: Frontiers in Oncology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2022.918499,
  title = {Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma},
  author = {Stefano Kim and Jihane Boustani and Dewi Vernerey and Véronique Vendrely and Ludovic Evesque and Eric Francois and Laurent Quero and Francois Ghiringhelli and Christelle de la Fouchardière and Laëtitia Dahan and Oliver Bouché and Benoist Chibaudel and Farid El Hajbi and Chloé Vernet and Magali Rebucci-Peixoto and Alexandra Feuersinger and Christophe Maritaz and Christophe Borg},
  year = {2022},
  journal = {Frontiers in Oncology},
  doi = {10.3389/fonc.2022.918499},
  url = {https://doi.org/10.3389/fonc.2022.918499}
}

RIS

TY  - JOUR
TI  - Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
AU  - Stefano Kim
AU  - Jihane Boustani
AU  - Dewi Vernerey
AU  - Véronique Vendrely
AU  - Ludovic Evesque
AU  - Eric Francois
AU  - Laurent Quero
AU  - Francois Ghiringhelli
AU  - Christelle de la Fouchardière
AU  - Laëtitia Dahan
AU  - Oliver Bouché
AU  - Benoist Chibaudel
AU  - Farid El Hajbi
AU  - Chloé Vernet
AU  - Magali Rebucci-Peixoto
AU  - Alexandra Feuersinger
AU  - Christophe Maritaz
AU  - Christophe Borg
PY  - 2022
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2022.918499
UR  - https://doi.org/10.3389/fonc.2022.918499
ER  -

APA

Kim, S., Boustani, J., Vernerey, D., Vendrely, V., Evesque, L., Francois, E., Quero, L., Ghiringhelli, F., Fouchardière, C. D. L., Dahan, L., Bouché, O., Chibaudel, B., Hajbi, F. E., Vernet, C., Rebucci-Peixoto, M., Feuersinger, A., Maritaz, C., & Borg, C. (2022). Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma. Frontiers in Oncology. https://doi.org/10.3389/fonc.2022.918499

Source records

crossref · retrieved 2026-09-26T20:03:45.206Z